Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Titan Pharmaceuticals (DE:TN7)
BERLIN:TN7
Holding DE:TN7?
Track your performance easily
TN7 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€4.40 - €19.03
Previous Close€7.48
Volume0.00
Average Volume (3M)94.00
Market Cap
€6.06M
Enterprise Value-€1.25M
Total Cash (Recent Filing)$8.10M
Total Debt (Recent Filing)$97.00K
Price to Earnings (P/E)―
Beta0.15
Next Earnings
Nov 11, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding15,016,295
10 Day Avg. Volume0
30 Day Avg. Volume94
Standard Deviation0.16
R-Squared0.08
Alpha-0.00583
Financial Highlights & Ratios
Price to Book (P/B)8.78
Price to Sales (P/S)127.79
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-4.11
Enterprise Value/Gross Profit-2.25
Enterprise Value/Ebitda0.62
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Titan Pharmaceuticals News
TN7 FAQ
What was Titan Pharmaceuticals’s price range in the past 12 months?
Titan Pharmaceuticals lowest stock price was €4.40 and its highest was €19.03 in the past 12 months.
What is Titan Pharmaceuticals’s market cap?
Currently, no data Available
When is Titan Pharmaceuticals’s upcoming earnings report date?
Titan Pharmaceuticals’s upcoming earnings report date is Nov 11, 2024 which is in 23 days.
How were Titan Pharmaceuticals’s earnings last quarter?
Titan Pharmaceuticals released its earnings results on Nov 13, 2023. The company reported -€0.02 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.02.
Is Titan Pharmaceuticals overvalued?
According to Wall Street analysts Titan Pharmaceuticals’s price is currently Overvalued.
Does Titan Pharmaceuticals pay dividends?
Titan Pharmaceuticals does not currently pay dividends.
What is Titan Pharmaceuticals’s EPS estimate?
Titan Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Titan Pharmaceuticals have?
Currently, no data Available
What happened to Titan Pharmaceuticals’s price movement after its last earnings report?
Titan Pharmaceuticals reported an EPS of -€0.02 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.152%.
Which hedge fund is a major shareholder of Titan Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:TN7
---
Titan Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.99%
12-Months-Change
Fundamentals
Return on Equity
-105.55%
Trailing 12-Months
Asset Growth
59.32%
Trailing 12-Months
Company Description
Titan Pharmaceuticals
Titan Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in development of therapeutics for the treatment of medical disorders. Its products include Probuphine, Ropinirole Implant, and T3 Implant. The company was founded by Louis R. Bucalo in February 7, 1992 and is headquartered in South San Francisco, CA.
---
TN7 Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Titan Pharmaceuticals
―
Palatin Technologies
―
Acasti Pharma
―
Onconova Therapeutics
―
Akari Therapeutics
―
---